Michael Graner
Concepts (418)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Extracellular Vesicles | 9 | 2024 | 148 | 3.700 |
Why?
| | Exosomes | 11 | 2020 | 105 | 2.690 |
Why?
| | Glioma | 10 | 2019 | 403 | 2.440 |
Why?
| | Cancer Vaccines | 17 | 2018 | 166 | 1.960 |
Why?
| | Molecular Chaperones | 17 | 2013 | 193 | 1.840 |
Why?
| | Brain Neoplasms | 12 | 2022 | 1268 | 1.700 |
Why?
| | Tumor Microenvironment | 5 | 2024 | 668 | 1.680 |
Why?
| | Brain Ischemia | 2 | 2025 | 343 | 1.330 |
Why?
| | Neoplasms | 11 | 2021 | 2701 | 1.310 |
Why?
| | Multiple Sclerosis | 8 | 2023 | 460 | 1.270 |
Why?
| | Cytokines | 7 | 2024 | 2084 | 1.050 |
Why?
| | Antigens, Neoplasm | 7 | 2018 | 317 | 0.960 |
Why?
| | Glioblastoma | 4 | 2022 | 341 | 0.940 |
Why?
| | Unfolded Protein Response | 3 | 2016 | 59 | 0.940 |
Why?
| | Interleukin-6 | 5 | 2025 | 786 | 0.940 |
Why?
| | Immunoglobulin G | 7 | 2023 | 903 | 0.930 |
Why?
| | HSP90 Heat-Shock Proteins | 4 | 2015 | 46 | 0.930 |
Why?
| | Proteome | 6 | 2024 | 471 | 0.920 |
Why?
| | Chordoma | 1 | 2024 | 14 | 0.890 |
Why?
| | Immune Tolerance | 2 | 2018 | 366 | 0.880 |
Why?
| | Cell Movement | 7 | 2024 | 972 | 0.870 |
Why?
| | Oligoclonal Bands | 4 | 2022 | 20 | 0.870 |
Why?
| | HSP70 Heat-Shock Proteins | 7 | 2015 | 74 | 0.860 |
Why?
| | Osteoblasts | 1 | 2024 | 131 | 0.850 |
Why?
| | Heat-Shock Proteins | 8 | 2013 | 143 | 0.830 |
Why?
| | Stroke | 2 | 2023 | 1137 | 0.810 |
Why?
| | Gene Expression Regulation, Neoplastic | 7 | 2024 | 1388 | 0.790 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2024 | 211 | 0.780 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 67 | 0.750 |
Why?
| | Cell Line, Tumor | 19 | 2024 | 3406 | 0.690 |
Why?
| | Extracellular Space | 4 | 2015 | 125 | 0.690 |
Why?
| | Proteomics | 6 | 2024 | 1113 | 0.690 |
Why?
| | Immunity | 4 | 2018 | 141 | 0.680 |
Why?
| | Meningioma | 1 | 2022 | 94 | 0.680 |
Why?
| | Antineoplastic Agents | 7 | 2021 | 2161 | 0.670 |
Why?
| | Meningeal Neoplasms | 1 | 2022 | 102 | 0.670 |
Why?
| | Astrocytes | 2 | 2019 | 215 | 0.610 |
Why?
| | Vacuolar Proton-Translocating ATPases | 1 | 2019 | 15 | 0.610 |
Why?
| | Antigen Presentation | 4 | 2018 | 219 | 0.600 |
Why?
| | Immunomodulation | 2 | 2018 | 99 | 0.580 |
Why?
| | Neoplasm Proteins | 2 | 2016 | 433 | 0.580 |
Why?
| | RNA, Neoplasm | 1 | 2018 | 79 | 0.570 |
Why?
| | MicroRNAs | 3 | 2018 | 680 | 0.530 |
Why?
| | T-Lymphocytes | 4 | 2018 | 1983 | 0.510 |
Why?
| | Brain Injuries | 1 | 2021 | 496 | 0.490 |
Why?
| | Calreticulin | 2 | 2013 | 28 | 0.450 |
Why?
| | Signal Transduction | 8 | 2020 | 5091 | 0.450 |
Why?
| | Cell Proliferation | 7 | 2018 | 2473 | 0.440 |
Why?
| | Humans | 59 | 2025 | 138631 | 0.430 |
Why?
| | Animals | 42 | 2023 | 37302 | 0.420 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 19 | 0.410 |
Why?
| | Mice, Inbred BALB C | 15 | 2014 | 1261 | 0.400 |
Why?
| | Leukocytes, Mononuclear | 1 | 2015 | 570 | 0.380 |
Why?
| | Dog Diseases | 1 | 2013 | 65 | 0.380 |
Why?
| | Autoantibodies | 1 | 2020 | 1454 | 0.380 |
Why?
| | Heat-Shock Response | 2 | 2015 | 75 | 0.370 |
Why?
| | Cerebellar Neoplasms | 1 | 2012 | 153 | 0.330 |
Why?
| | Medulloblastoma | 1 | 2012 | 193 | 0.330 |
Why?
| | Stress, Physiological | 1 | 2013 | 454 | 0.320 |
Why?
| | Dendritic Cells | 12 | 2008 | 492 | 0.310 |
Why?
| | Mice | 26 | 2023 | 17841 | 0.310 |
Why?
| | Transcription Factors | 2 | 2014 | 1707 | 0.310 |
Why?
| | Mycobacterium tuberculosis | 7 | 2015 | 317 | 0.300 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2013 | 800 | 0.290 |
Why?
| | Tuberculosis | 4 | 2015 | 280 | 0.290 |
Why?
| | Carrier Proteins | 2 | 2009 | 739 | 0.270 |
Why?
| | Transforming Growth Factor beta | 4 | 2024 | 487 | 0.260 |
Why?
| | Peptides | 5 | 2024 | 984 | 0.260 |
Why?
| | Isoelectric Focusing | 3 | 2015 | 31 | 0.250 |
Why?
| | Neoplasms, Experimental | 3 | 2006 | 174 | 0.250 |
Why?
| | Lymphocyte Activation | 5 | 2012 | 1145 | 0.250 |
Why?
| | Histocompatibility Antigens Class I | 3 | 2018 | 203 | 0.250 |
Why?
| | Interferon-gamma | 8 | 2015 | 789 | 0.240 |
Why?
| | Immunotherapy | 3 | 2021 | 631 | 0.230 |
Why?
| | Case-Control Studies | 5 | 2021 | 3580 | 0.230 |
Why?
| | Oligopeptides | 4 | 2007 | 272 | 0.230 |
Why?
| | Female | 30 | 2025 | 73891 | 0.230 |
Why?
| | Tetraspanin 28 | 1 | 2024 | 6 | 0.220 |
Why?
| | alpha-Synuclein | 1 | 2024 | 41 | 0.220 |
Why?
| | Amino Acid Sequence | 6 | 2020 | 2162 | 0.220 |
Why?
| | Fusion Proteins, bcr-abl | 4 | 2007 | 70 | 0.210 |
Why?
| | Albumins | 1 | 2004 | 116 | 0.210 |
Why?
| | Middle Aged | 14 | 2025 | 33788 | 0.210 |
Why?
| | Apoptosis | 5 | 2023 | 2558 | 0.210 |
Why?
| | Integrins | 3 | 1998 | 95 | 0.210 |
Why?
| | Leukemia, B-Cell | 2 | 2000 | 13 | 0.210 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 1 | 2023 | 28 | 0.200 |
Why?
| | Sensitivity and Specificity | 3 | 2025 | 1958 | 0.200 |
Why?
| | Neuroblastoma | 2 | 2023 | 160 | 0.190 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2023 | 76 | 0.190 |
Why?
| | Aged, 80 and over | 3 | 2025 | 7683 | 0.190 |
Why?
| | Drosophila Proteins | 3 | 1998 | 202 | 0.190 |
Why?
| | Tuberculosis, Pleural | 2 | 2014 | 6 | 0.190 |
Why?
| | Transferases | 1 | 2022 | 33 | 0.190 |
Why?
| | Membrane Glycoproteins | 4 | 2015 | 500 | 0.190 |
Why?
| | Tuberculosis, Pulmonary | 3 | 2012 | 142 | 0.180 |
Why?
| | Lung Neoplasms | 2 | 2013 | 2531 | 0.180 |
Why?
| | Organ Specificity | 2 | 2020 | 310 | 0.180 |
Why?
| | Male | 19 | 2025 | 68214 | 0.180 |
Why?
| | Leukemia | 4 | 2006 | 241 | 0.180 |
Why?
| | Melanoma | 2 | 2024 | 766 | 0.180 |
Why?
| | Peptide Fragments | 4 | 2020 | 691 | 0.170 |
Why?
| | Epitopes | 2 | 2020 | 476 | 0.170 |
Why?
| | Blotting, Western | 4 | 2009 | 1229 | 0.170 |
Why?
| | Tissue Plasminogen Activator | 1 | 2023 | 231 | 0.170 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2013 | 865 | 0.170 |
Why?
| | Cell Extracts | 3 | 2006 | 21 | 0.170 |
Why?
| | Biomarkers | 5 | 2025 | 4111 | 0.170 |
Why?
| | Ultracentrifugation | 1 | 2020 | 52 | 0.170 |
Why?
| | Laser Capture Microdissection | 1 | 2020 | 32 | 0.170 |
Why?
| | Extracellular Matrix Proteins | 2 | 1998 | 155 | 0.160 |
Why?
| | Plasma Cells | 1 | 2020 | 73 | 0.160 |
Why?
| | Tumor Cells, Cultured | 7 | 2007 | 949 | 0.160 |
Why?
| | Aged | 7 | 2025 | 24181 | 0.160 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2012 | 1101 | 0.160 |
Why?
| | Antibody Specificity | 1 | 2020 | 187 | 0.160 |
Why?
| | Peptide Library | 1 | 2020 | 95 | 0.160 |
Why?
| | Protein Transport | 2 | 2019 | 441 | 0.160 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 867 | 0.160 |
Why?
| | Virus Latency | 1 | 2020 | 79 | 0.160 |
Why?
| | T-Lymphocytes, Cytotoxic | 8 | 2015 | 174 | 0.150 |
Why?
| | Prognosis | 2 | 2021 | 4015 | 0.150 |
Why?
| | Cells, Cultured | 6 | 2015 | 4174 | 0.150 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2020 | 98 | 0.150 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2007 | 125 | 0.150 |
Why?
| | Bacteriophages | 1 | 2020 | 99 | 0.150 |
Why?
| | Receptors, Purinergic | 1 | 2018 | 19 | 0.150 |
Why?
| | Lymphoma, B-Cell | 1 | 2000 | 127 | 0.150 |
Why?
| | Tenascin | 1 | 1998 | 15 | 0.150 |
Why?
| | Transcription, Genetic | 3 | 2014 | 1462 | 0.140 |
Why?
| | Laminin | 1 | 1998 | 71 | 0.140 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 981 | 0.140 |
Why?
| | Receptors, Fc | 1 | 2018 | 55 | 0.140 |
Why?
| | Antigen-Presenting Cells | 1 | 2018 | 157 | 0.140 |
Why?
| | Milk | 1 | 2018 | 123 | 0.140 |
Why?
| | Alzheimer Disease | 1 | 2024 | 570 | 0.140 |
Why?
| | DNA, Viral | 1 | 2020 | 369 | 0.140 |
Why?
| | Alternative Splicing | 2 | 2006 | 227 | 0.140 |
Why?
| | Drug Carriers | 1 | 2018 | 126 | 0.140 |
Why?
| | Immune System | 1 | 2019 | 181 | 0.140 |
Why?
| | Cell Hypoxia | 2 | 2015 | 231 | 0.130 |
Why?
| | Nanoparticles | 2 | 2020 | 468 | 0.130 |
Why?
| | Biological Transport | 1 | 2018 | 403 | 0.130 |
Why?
| | Autoantigens | 1 | 2020 | 423 | 0.130 |
Why?
| | Ovarian Neoplasms | 2 | 2017 | 575 | 0.130 |
Why?
| | Prostatic Neoplasms | 2 | 2015 | 1048 | 0.130 |
Why?
| | Time Factors | 2 | 2025 | 6877 | 0.130 |
Why?
| | DNA Methylation | 1 | 2022 | 637 | 0.130 |
Why?
| | Antigens, Bacterial | 2 | 2015 | 125 | 0.130 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 375 | 0.130 |
Why?
| | Herpesvirus 3, Human | 1 | 2020 | 331 | 0.130 |
Why?
| | Inflammation | 2 | 2019 | 2856 | 0.120 |
Why?
| | Adenosine Triphosphate | 1 | 2018 | 489 | 0.120 |
Why?
| | Mass Spectrometry | 2 | 2016 | 741 | 0.120 |
Why?
| | Protein Array Analysis | 1 | 2015 | 56 | 0.120 |
Why?
| | Antigens, Surface | 1 | 2015 | 153 | 0.120 |
Why?
| | Lymphocytes | 1 | 2017 | 399 | 0.120 |
Why?
| | DNA | 1 | 2022 | 1449 | 0.110 |
Why?
| | Brain | 3 | 2020 | 2782 | 0.110 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 452 | 0.110 |
Why?
| | Neurons | 2 | 2022 | 1603 | 0.110 |
Why?
| | Alkynes | 1 | 2014 | 57 | 0.110 |
Why?
| | Granuloma | 1 | 2015 | 97 | 0.110 |
Why?
| | Azides | 1 | 2014 | 47 | 0.110 |
Why?
| | RNA, Messenger | 5 | 2020 | 2816 | 0.110 |
Why?
| | Acute Lung Injury | 1 | 2017 | 299 | 0.110 |
Why?
| | Click Chemistry | 1 | 2014 | 50 | 0.110 |
Why?
| | Lung | 3 | 2017 | 4086 | 0.110 |
Why?
| | BCG Vaccine | 2 | 2010 | 25 | 0.110 |
Why?
| | Adherens Junctions | 1 | 2013 | 25 | 0.110 |
Why?
| | Interferon-gamma Release Tests | 1 | 2014 | 32 | 0.100 |
Why?
| | Basigin | 1 | 2013 | 25 | 0.100 |
Why?
| | Intestinal Mucosa | 1 | 2018 | 621 | 0.100 |
Why?
| | Pleural Effusion | 1 | 2014 | 56 | 0.100 |
Why?
| | Flow Cytometry | 3 | 2012 | 1197 | 0.100 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2013 | 69 | 0.100 |
Why?
| | Adult | 13 | 2024 | 38291 | 0.100 |
Why?
| | Dacarbazine | 1 | 2013 | 97 | 0.100 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2013 | 365 | 0.100 |
Why?
| | Lipogenesis | 1 | 2013 | 61 | 0.100 |
Why?
| | Triglycerides | 1 | 2015 | 515 | 0.100 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 131 | 0.100 |
Why?
| | Drosophila | 3 | 1998 | 154 | 0.100 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2013 | 117 | 0.100 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2012 | 14 | 0.100 |
Why?
| | ErbB Receptors | 2 | 2006 | 613 | 0.100 |
Why?
| | Prostate | 1 | 2013 | 174 | 0.100 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2013 | 165 | 0.100 |
Why?
| | Neoplasm Grading | 1 | 2013 | 306 | 0.090 |
Why?
| | Mice, Inbred C57BL | 6 | 2017 | 5807 | 0.090 |
Why?
| | Tumor Burden | 1 | 2013 | 307 | 0.090 |
Why?
| | Dogs | 1 | 2013 | 426 | 0.090 |
Why?
| | Liver | 2 | 2013 | 1876 | 0.090 |
Why?
| | B-Lymphocytes | 2 | 2022 | 856 | 0.090 |
Why?
| | Neutrophils | 1 | 2017 | 1279 | 0.090 |
Why?
| | B-Lymphocyte Subsets | 1 | 2012 | 77 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2023 | 10938 | 0.090 |
Why?
| | Cell Line | 4 | 2020 | 2874 | 0.090 |
Why?
| | Epithelial Cells | 1 | 2017 | 1102 | 0.090 |
Why?
| | Mice, Nude | 3 | 2007 | 689 | 0.090 |
Why?
| | Cell Survival | 2 | 2012 | 1129 | 0.090 |
Why?
| | Gene Regulatory Networks | 1 | 2013 | 310 | 0.090 |
Why?
| | Phenotype | 3 | 2018 | 3160 | 0.090 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2010 | 37 | 0.090 |
Why?
| | Th17 Cells | 1 | 2012 | 108 | 0.090 |
Why?
| | Radiography | 1 | 2013 | 846 | 0.080 |
Why?
| | RNA-Binding Proteins | 1 | 2014 | 428 | 0.080 |
Why?
| | Interleukin-17 | 1 | 2011 | 120 | 0.080 |
Why?
| | Oxygen | 1 | 2015 | 967 | 0.080 |
Why?
| | Latent Tuberculosis | 1 | 2010 | 68 | 0.080 |
Why?
| | Receptors, Interleukin-6 | 1 | 2009 | 46 | 0.080 |
Why?
| | Immunohistochemistry | 3 | 2009 | 1731 | 0.080 |
Why?
| | Immunity, Innate | 1 | 2015 | 828 | 0.080 |
Why?
| | Tissue Array Analysis | 1 | 2009 | 51 | 0.080 |
Why?
| | Interleukins | 1 | 2011 | 251 | 0.080 |
Why?
| | Mycobacterium bovis | 1 | 2009 | 17 | 0.080 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2008 | 108 | 0.080 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2009 | 137 | 0.080 |
Why?
| | Cross-Priming | 1 | 2008 | 16 | 0.080 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 112 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2023 | 856 | 0.070 |
Why?
| | Antigens, Differentiation | 1 | 2008 | 81 | 0.070 |
Why?
| | Toll-Like Receptor 2 | 1 | 2009 | 116 | 0.070 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2009 | 430 | 0.070 |
Why?
| | Carcinoma, Lewis Lung | 2 | 2005 | 15 | 0.070 |
Why?
| | Neoplasm Transplantation | 3 | 2006 | 251 | 0.070 |
Why?
| | Blood-Brain Barrier | 1 | 2008 | 140 | 0.070 |
Why?
| | Immunization | 3 | 2015 | 405 | 0.070 |
Why?
| | Immunotherapy, Active | 1 | 2007 | 9 | 0.070 |
Why?
| | Tissue Extracts | 1 | 2007 | 21 | 0.070 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1476 | 0.070 |
Why?
| | Hypoxia | 1 | 2013 | 1137 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 1 | 2008 | 230 | 0.060 |
Why?
| | Tissue Distribution | 2 | 2018 | 333 | 0.060 |
Why?
| | Cell Membrane | 1 | 2009 | 715 | 0.060 |
Why?
| | Vitamin E | 1 | 2005 | 123 | 0.060 |
Why?
| | T-Lymphocyte Subsets | 1 | 2007 | 417 | 0.060 |
Why?
| | Integrin alpha Chains | 3 | 1998 | 24 | 0.050 |
Why?
| | Spleen | 2 | 2004 | 523 | 0.050 |
Why?
| | Amyloidogenic Proteins | 1 | 2024 | 16 | 0.050 |
Why?
| | Quinazolines | 1 | 2005 | 250 | 0.050 |
Why?
| | Piperidines | 1 | 2005 | 215 | 0.050 |
Why?
| | Molecular Sequence Data | 3 | 2015 | 2928 | 0.050 |
Why?
| | Central Nervous System Neoplasms | 1 | 2005 | 165 | 0.050 |
Why?
| | Kinetics | 2 | 2006 | 1654 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2015 | 501 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4333 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 2 | 2004 | 350 | 0.050 |
Why?
| | Plasma | 1 | 2024 | 221 | 0.050 |
Why?
| | Interleukin-12 | 3 | 2008 | 123 | 0.050 |
Why?
| | Piperazines | 1 | 2004 | 349 | 0.050 |
Why?
| | Recombinant Proteins | 2 | 2020 | 1357 | 0.040 |
Why?
| | Survival Analysis | 2 | 2006 | 1313 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2002 | 121 | 0.040 |
Why?
| | Head and Neck Neoplasms | 1 | 2006 | 554 | 0.040 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2006 | 646 | 0.040 |
Why?
| | Cell Division | 1 | 2003 | 791 | 0.040 |
Why?
| | Chromatography | 1 | 2000 | 23 | 0.040 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 2020 | 12 | 0.040 |
Why?
| | Chemical Precipitation | 1 | 2020 | 38 | 0.040 |
Why?
| | Pyrimidines | 1 | 2004 | 476 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2005 | 2045 | 0.040 |
Why?
| | Lymphocyte Culture Test, Mixed | 3 | 2007 | 51 | 0.040 |
Why?
| | Injections, Spinal | 1 | 2020 | 108 | 0.040 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 339 | 0.040 |
Why?
| | bcl-X Protein | 1 | 2020 | 43 | 0.040 |
Why?
| | Immediate-Early Proteins | 1 | 2020 | 49 | 0.040 |
Why?
| | Lipids | 1 | 2004 | 674 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2006 | 661 | 0.040 |
Why?
| | Electron Transport Complex IV | 1 | 2020 | 60 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2023 | 321 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2000 | 164 | 0.040 |
Why?
| | Vaccination | 1 | 2008 | 1435 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2020 | 165 | 0.040 |
Why?
| | Ligands | 2 | 1998 | 665 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2000 | 151 | 0.040 |
Why?
| | Viral Envelope Proteins | 1 | 2020 | 97 | 0.040 |
Why?
| | China | 2 | 2010 | 213 | 0.040 |
Why?
| | Up-Regulation | 2 | 2013 | 851 | 0.040 |
Why?
| | Caspase 3 | 1 | 2020 | 250 | 0.040 |
Why?
| | Carbocyanines | 1 | 2018 | 33 | 0.040 |
Why?
| | Ribonucleoproteins | 1 | 2000 | 104 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 238 | 0.040 |
Why?
| | Calcium-Binding Proteins | 1 | 2000 | 214 | 0.040 |
Why?
| | Biological Availability | 1 | 2018 | 138 | 0.040 |
Why?
| | Permeability | 1 | 2018 | 161 | 0.040 |
Why?
| | Protein Conformation | 2 | 1998 | 944 | 0.040 |
Why?
| | Solubility | 1 | 2018 | 241 | 0.040 |
Why?
| | RNA Transport | 1 | 2017 | 23 | 0.030 |
Why?
| | Young Adult | 5 | 2014 | 13321 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 98 | 0.030 |
Why?
| | Th1 Cells | 2 | 2012 | 142 | 0.030 |
Why?
| | Fluorescent Dyes | 1 | 2018 | 320 | 0.030 |
Why?
| | Cell Adhesion | 1 | 1998 | 465 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 329 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 789 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 2602 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2020 | 649 | 0.030 |
Why?
| | Cattle | 1 | 2018 | 996 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2007 | 193 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 316 | 0.030 |
Why?
| | Blood Proteins | 1 | 2017 | 248 | 0.030 |
Why?
| | Antibodies, Monoclonal | 3 | 2008 | 1437 | 0.030 |
Why?
| | Fetus | 1 | 2020 | 801 | 0.030 |
Why?
| | Pharmaceutical Vehicles | 1 | 2014 | 12 | 0.030 |
Why?
| | Muscle Contraction | 1 | 1998 | 435 | 0.030 |
Why?
| | HSP72 Heat-Shock Proteins | 2 | 2007 | 32 | 0.030 |
Why?
| | Fibroblasts | 1 | 2020 | 1001 | 0.030 |
Why?
| | Cycloaddition Reaction | 1 | 2014 | 28 | 0.030 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2014 | 104 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 2014 | 204 | 0.030 |
Why?
| | Fluorescence | 1 | 2015 | 159 | 0.030 |
Why?
| | Protein Binding | 1 | 2000 | 2236 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2014 | 124 | 0.030 |
Why?
| | Tetraspanins | 1 | 2013 | 19 | 0.030 |
Why?
| | Annexin A2 | 1 | 2013 | 16 | 0.030 |
Why?
| | Phosphatidylcholines | 1 | 2014 | 136 | 0.030 |
Why?
| | Copper | 1 | 2014 | 110 | 0.030 |
Why?
| | Metalloproteases | 1 | 2013 | 42 | 0.030 |
Why?
| | Choline | 1 | 2014 | 131 | 0.030 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2015 | 184 | 0.030 |
Why?
| | Cross-Linking Reagents | 1 | 2014 | 215 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2000 | 1153 | 0.030 |
Why?
| | Bone Marrow Cells | 2 | 2007 | 325 | 0.030 |
Why?
| | Particle Size | 1 | 2014 | 391 | 0.030 |
Why?
| | Surface Properties | 1 | 2014 | 411 | 0.030 |
Why?
| | Feedback, Physiological | 1 | 2013 | 81 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2013 | 241 | 0.020 |
Why?
| | Liposomes | 1 | 2014 | 218 | 0.020 |
Why?
| | Doxorubicin | 1 | 2014 | 351 | 0.020 |
Why?
| | CD5 Antigens | 1 | 2012 | 9 | 0.020 |
Why?
| | Ionomycin | 1 | 2012 | 22 | 0.020 |
Why?
| | Antigens, CD1d | 1 | 2012 | 68 | 0.020 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2012 | 156 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2012 | 167 | 0.020 |
Why?
| | Cell Aggregation | 1 | 2011 | 26 | 0.020 |
Why?
| | Pneumonia | 1 | 2017 | 643 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 359 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2023 | 6143 | 0.020 |
Why?
| | Antigens, CD19 | 1 | 2012 | 130 | 0.020 |
Why?
| | Phosphorylation | 2 | 2005 | 1770 | 0.020 |
Why?
| | Interleukin-2 | 1 | 2012 | 451 | 0.020 |
Why?
| | Prospective Studies | 2 | 2014 | 7639 | 0.020 |
Why?
| | Monophenol Monooxygenase | 1 | 2008 | 8 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 209 | 0.020 |
Why?
| | Radioimmunotherapy | 1 | 2008 | 21 | 0.020 |
Why?
| | Genes, Insect | 2 | 1998 | 22 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 2039 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2009 | 271 | 0.020 |
Why?
| | Vaccines, DNA | 1 | 2008 | 32 | 0.020 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2008 | 80 | 0.020 |
Why?
| | Immunization, Passive | 1 | 2008 | 92 | 0.020 |
Why?
| | Vaccines, Subunit | 1 | 2008 | 50 | 0.020 |
Why?
| | Wings, Animal | 2 | 1998 | 35 | 0.020 |
Why?
| | Immunotoxins | 1 | 2008 | 56 | 0.020 |
Why?
| | Adolescent | 3 | 2012 | 21528 | 0.020 |
Why?
| | Calbindin 2 | 1 | 2007 | 8 | 0.020 |
Why?
| | Down-Regulation | 1 | 2009 | 638 | 0.020 |
Why?
| | S100 Calcium Binding Protein G | 1 | 2007 | 8 | 0.020 |
Why?
| | Egg Proteins | 1 | 2007 | 17 | 0.020 |
Why?
| | HLA-A2 Antigen | 1 | 2007 | 49 | 0.020 |
Why?
| | Animals, Genetically Modified | 2 | 1998 | 243 | 0.020 |
Why?
| | Ovalbumin | 1 | 2007 | 190 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2012 | 1248 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2007 | 225 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1236 | 0.020 |
Why?
| | Transplantation, Isogeneic | 1 | 2006 | 16 | 0.020 |
Why?
| | Antigen-Antibody Reactions | 1 | 2006 | 55 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2006 | 194 | 0.020 |
Why?
| | Drug Synergism | 1 | 2007 | 371 | 0.020 |
Why?
| | Mutation | 3 | 2006 | 3998 | 0.020 |
Why?
| | Hot Temperature | 1 | 2008 | 394 | 0.020 |
Why?
| | Dosage Forms | 1 | 2005 | 9 | 0.010 |
Why?
| | Tocopherols | 1 | 2005 | 26 | 0.010 |
Why?
| | Ki-67 Antigen | 1 | 2005 | 110 | 0.010 |
Why?
| | alpha-Macroglobulins | 1 | 2005 | 24 | 0.010 |
Why?
| | Ultrasonics | 1 | 2005 | 50 | 0.010 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2008 | 388 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 149 | 0.010 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2007 | 206 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 183 | 0.010 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2004 | 51 | 0.010 |
Why?
| | HeLa Cells | 1 | 2006 | 639 | 0.010 |
Why?
| | Imatinib Mesylate | 1 | 2004 | 80 | 0.010 |
Why?
| | Neovascularization, Pathologic | 1 | 2005 | 296 | 0.010 |
Why?
| | Ependymoma | 1 | 2005 | 163 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1093 | 0.010 |
Why?
| | Benzamides | 1 | 2004 | 213 | 0.010 |
Why?
| | Cell-Free System | 1 | 2003 | 55 | 0.010 |
Why?
| | Chaperonin 60 | 1 | 2002 | 13 | 0.010 |
Why?
| | CD40 Antigens | 1 | 2003 | 89 | 0.010 |
Why?
| | Protein Folding | 1 | 2003 | 279 | 0.010 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2002 | 193 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2861 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2703 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2004 | 1237 | 0.010 |
Why?
| | Adjuvants, Immunologic | 1 | 2002 | 237 | 0.010 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2007 | 912 | 0.010 |
Why?
| | Immunity, Cellular | 1 | 2002 | 270 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2006 | 1755 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2007 | 2000 | 0.010 |
Why?
| | Pupa | 1 | 1998 | 12 | 0.010 |
Why?
| | Genes, Lethal | 1 | 1998 | 30 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2001 | 662 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 1998 | 135 | 0.010 |
Why?
| | DNA, Complementary | 1 | 1998 | 276 | 0.010 |
Why?
| | Abdomen | 1 | 1998 | 132 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1998 | 393 | 0.010 |
Why?
| | Larva | 1 | 1998 | 235 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 1748 | 0.010 |
Why?
| | Cytoplasm | 1 | 1998 | 270 | 0.010 |
Why?
| | Muscles | 1 | 1998 | 332 | 0.010 |
Why?
| | HIV Infections | 1 | 2010 | 2944 | 0.010 |
Why?
| | Retina | 1 | 1998 | 303 | 0.010 |
Why?
| | Base Sequence | 1 | 1998 | 2182 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 1998 | 875 | 0.010 |
Why?
| | Risk Factors | 1 | 2006 | 10395 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2006 | 15859 | 0.000 |
Why?
|
|
Graner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|